Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 790 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Therapy for head and neck cancer Clear all
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

NCT00077428
View directory record Official record
Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
Interventions
bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 16, 2026, 2:56 AM EDT
Recruiting Phase 1 Interventional

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

NCT04754321
View directory record Official record
Conditions
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma
Interventions
External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab, Quality-of-Life Assessment, Salvage Surgery
Radiation · Biological · Other + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 16, 2026, 2:56 AM EDT
Terminated Phase 3 Interventional

Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer

NCT02655068
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
PET/CT, Computed Tomography (CT)
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer

NCT00490282
View directory record Official record
Conditions
Head and Neck Cancer, Oropharyngeal Cancer
Interventions
Intensity Modulated Radiation Therapy, Adaptive Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 16, 2026, 2:56 AM EDT
Terminated Phase 1 Interventional

MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer

NCT00896350
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Standard Care Chemoradiation
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

NCT01185171
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ZD 1839 500mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients

NCT00721799
View directory record Official record
Conditions
Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
Interventions
18F-Fluorothymidine PET scan
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia

NCT07802977
View directory record Official record
Conditions
Xerostomia, Head and Neck Squamous Cell Carcinoma
Interventions
Dexamethasone 4mg/mL, Dexamethasone 10mg/mL
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Effects of Infusion Timing on Treatment Response in Solid Tumors

NCT07630168
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Resectable Head and Neck Squamous-cell Carcinoma
Interventions
PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM, PD-1 inhibitor monotherapy - 2 cycles after 3 PM
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

NCT02784288
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Cancer
Interventions
Neck Dissection, Standard-of-Care (SOC) Transoral Surgery of Primary Site, SOC Radiation, SOC Carboplatin, SOC Paclitaxel, Videofluoroscopy
Procedure · Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 16, 2026, 2:56 AM EDT
Completed No phase listed Observational

Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.

NCT04549246
View directory record Official record
Conditions
Radiation Therapy Complication, Tumor Neck, Tumor Abdomen
Interventions
Spatially Fractionated Radiation (GRID) Therapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 16, 2026, 2:56 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

NCT03745690
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Image-Guided Surgery, Indocyanine Green Drug
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment

NCT03332160
View directory record Official record
Conditions
Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Lymphedema
Interventions
Flexitouch head and neck lymphedema treatment system, Standard home lymphedema care
Device · Other
Lead sponsor
Tactile Medical
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Springfield, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Expiratory Muscle Strength Training in Improving Bulbar Function and Quality of Life in Patients With Head and Neck Cancer

NCT03175289
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm
Interventions
Best Practice, Educational Intervention, Exercise Intervention, Expiratory Muscle Strength Training, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years to 78 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccination With Flt3L, Radiation, and Poly-ICLC

NCT03789097
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Flt3L, Radiation, Poly ICLC
Drug · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

NCT02799095
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ALKS 4230, ALKS 4230 + pembrolizumab
Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 16, 2026, 2:56 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

NCT00970502
View directory record Official record
Conditions
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms, Cancer of the Head
Interventions
erlotinib + celecoxib
Drug
Lead sponsor
Johnny Kao
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

NCT03719690
View directory record Official record
Conditions
HRAS Gene Mutation, HNSCC
Interventions
Tipifarnib, HRAS Detection Assay
Drug · Device
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 16, 2026, 2:56 AM EDT
Withdrawn Phase 2 Interventional

S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer

NCT00084435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Los Angeles, California • Decatur, Illinois • Springfield, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 3 Interventional

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

NCT00006481
View directory record Official record
Conditions
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions
Biafine cream, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
240
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

NCT02531906
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Pain, Stomatitis
Interventions
Gabapentin, Methadone Hydrochloride, Oxycodone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 16, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparing Over-the-counter Dry Mouth Remedies After Radiation

NCT00595933
View directory record Official record
Conditions
Xerostomia
Interventions
sugar-free chewing gum, chewing gum, mouth rinse, mouth spray
Other · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 16, 2026, 2:56 AM EDT